Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002881149 | SCV003233978 | pathogenic | MHC class II deficiency | 2022-09-12 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 4 of the RFX5 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. For these reasons, this variant has been classified as Pathogenic. Studies have shown that disruption of this splice site results in deletion of 4 nucleotides and introduces a premature termination codon (PMID: 10079298). The resulting mRNA is expected to undergo nonsense-mediated decay. Studies have shown that disruption of this splice site alters RFX5 gene expression (PMID: 10079298). Disruption of this splice site has been observed in individual(s) with MHC class II deficiency (PMID: 10079298). This variant is not present in population databases (gnomAD no frequency). |